<DOC>
	<DOCNO>NCT00609856</DOCNO>
	<brief_summary>Pioglitazone insulin glargine equally effective achieve glycemic control secondary drug failure type 2 diabetes mechanisms action different .</brief_summary>
	<brief_title>Pioglitazone vs. Insulin Glargine Treatment Secondary Drug Failure Type 2 Diabetes</brief_title>
	<detailed_description>The present study undertaken ass difference insulin glargine vs. pioglitazone affect : - Beta-cell function measure proinsulin/insulin , homeostasis model assessment insulin secretion ( HOMA Î²-cell ) glucagon stimulate C-peptide test - Insulin sensitivity measure adiponectin , homeostasis model assessment insulin resistance ( HOMA-IR ) insulin tolerance test - Surrogate marker cardiovascular disease measure BNP , NT-pro BNP plasma lipid profile add-on therapy patient T2D secondary drug failure . The patient ' satisfaction treatment also survey .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>type 2 diabetes inadequately control 50 % maximaldose insulin secretagogue metformin heart failure ( NYHA IIIV )</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2008</verification_date>
</DOC>